Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people who stop semaglutide begin regaining weight within weeks to a few months. Clinical trial data show that, on average, participants regained around two-thirds of the weight they had lost within a year of stopping — because the appetite-suppressing effects of the medicine wear off as it clears your system, not because anything permanent has changed in your biology. These medicines are prescription-only and are always taken under clinical supervision; a prescriber assesses whether continuing or stopping is right for you at any given point.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The short answer is yes, for most people, and the process starts sooner than many expect. Once semaglutide is no longer being dosed, the GLP-1 receptor stimulation that was suppressing appetite and slowing gastric emptying fades. Hunger returns, often to pre-treatment levels. The medicine itself has a half-life of roughly one week, so by the time four or five weeks have passed it has largely cleared your system, and you can read more about that process on our page covering how long semaglutide stays in your system after stopping.
The clearest evidence comes from the STEP 4 trial, published in the New England Journal of Medicine. Participants who had lost significant weight on semaglutide 2.4mg were randomised either to continue or to switch to placebo. Those who stopped regained an average of about two-thirds of their prior weight loss over the following 48 weeks. Blood pressure, blood sugar and other health markers also drifted back toward baseline. That trajectory was fairly consistent regardless of how much weight each person had lost, the regain reflected the biology of obesity reasserting itself rather than any individual failure.
How quickly regain starts (not just how much) is worth understanding, because the pattern matters for planning. A practical check you can do right now: note your current weight and set a reminder to weigh yourself on the same day, same time, four weeks after any planned pause. That single data point tells you more than weeks of guessing.
This is a question our prescribers hear regularly, and the honest answer is that for most people, lifestyle changes alone are not enough to counteract the biological drive to regain weight. Obesity involves hormonal and neurological adaptations (lower resting metabolic rate, higher circulating ghrelin, altered satiety signalling) that persist well beyond the period of active treatment. Semaglutide works partly by overriding some of those signals; when the medicine stops, the underlying biology does not.
That does not mean the work done during treatment is wasted. People who use the treatment period to build sustainable habits (consistent protein intake, regular physical activity, better sleep) tend to regain more slowly and hold on to more of their loss. But for a condition as biologically driven as obesity, habit change alone rarely replaces the pharmacological effect. The NICE appraisal of semaglutide for weight management notes this directly, framing the medicine as a long-term tool within a broader programme rather than a short course with a clean exit. If you are curious about whether it is realistic to maintain your weight loss after stopping Wegovy, that question is explored in detail on its own page. If you are curious about what long-term maintenance looks like in practice, the detail is covered on our page about keeping weight off after stopping Wegovy.
Stopping well (with a plan) is meaningfully different from stopping abruptly. A prescriber can help you assess where you are and what continuation, pausing or transitioning might look like for you specifically.
Duration of treatment does appear to matter, though not in the way people often assume. It is not that a longer course permanently resets your biology. Rather, a longer period on treatment gives you more time to lose weight, to stabilise at a lower weight, and to embed the habits that slow regain. Someone who has been at their lower weight for 18 months has a different physiological baseline from someone who stopped after three months.
There is also the question of dose. People who reached and tolerated the full 2.4mg maintenance dose (or the newer 7.2mg dose, which produced around 20.7% average weight loss in its clinical trials) lost more overall. But greater loss does not protect against proportional regain once the medicine stops. The fraction that returns is remarkably consistent in the trial data.
A related question is timing: not just how much comes back but when weight regain typically begins after stopping semaglutide. The first noticeable rise tends to appear within four to eight weeks for most people, accelerating over the following months. Understanding that window helps with planning the next step, whether that is continuing, pausing with close monitoring, or transitioning to a different treatment approach. For an overview of the treatment itself and how semaglutide works as a weight-loss medicine, our Wegovy page covers the full picture.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.